SELDI蛋白芯片技术可有效筛选血清中特异性蛋白标志物，为建立卵巢癌的诊断模型提供可靠的技术平台。
2.4 乳腺癌
CA153用于乳腺癌的检测，其灵敏度23％，特异性69％，只能用于监测治疗效果和复发情况。LI等[23]对169例血清进行检测，其中乳腺癌103例，正常人41例，其它乳腺疾病25例，结果发现3个潜在的新肿瘤标志物，将其组成蛋白组用来诊断分析，其灵敏度93％，特异性91％，提示该方法可用于筛选乳腺癌生物标记物。
细针穿刺细胞学检查（FNA）是一种简便、应用较广的肿瘤辅助诊断方法，但对浸润性癌与非浸润性癌的诊断不确定，也难以得到反映乳腺癌生物学特性的一些分子生物学检查所需的组织标本，因此在Fowler等[24]的研究中，对24例由FNA获取的吸出物采用甲醛进行初步的固定，然后在一定条件下进行变性等处理，再采用SELDI质谱仪进行检测，结果发现利用所得的图谱有助于良恶性乳腺疾病的鉴别诊断，同时得到一种较简单的获取组织蛋白的方法，但需更多的试验进行进一步的论证。
此外，SELDI技术还被应用于前列腺癌[25]，结肠癌[26]、头颈部肿瘤[27]、胰腺癌[28]、胃癌[29]等的研究中，均显示该技术有助于肿瘤的早期辅助诊断。
3、前景及展望
蛋白芯片SELDI技术除应用于肿瘤早期诊断中外，在其他疾病的研究（如艾滋病、老年性痴呆）、疗效检测、发病机制探讨、新药研发和基础理论研究等方面亦具有广泛应用。但是由于是一项新出现的技术，也存在一些不足之处，如小分子量蛋白质的检测仍然没有像大分子量蛋白质检测那么容易，质谱检测出的蛋白质不能直接鉴定，必须通过后续的检测方法判断蛋白质的种类，另外，目前全世界SELDI-TOP-MS实验室在质控血清建立及仪器标准化状态、自动化应用等方面存在着不统一的标准[30]，因此，对于SELDI发现的生物标记物在用于临床诊断及其干预治疗之前，必须进行严格的多中心和三期临床质控验证。随着该技术在各种疾病中的纵深研究和技术理论不断的完善和发展，通过大规模研究蛋白质性质、蛋白质之间相互作用及肿瘤标志物的论证和研究，推动蛋白质组学、基因组学和肿瘤学的研究进程，发现和确定越来越多的组织特异的新肿瘤标记物，从而实现疾病尤其是肿瘤的早期诊断，满足癌症病人的需要。
【参考文献】
[1] Powell K．Proteomics delivers on promise of cancer biomarkers[J]. Nature Med, 2003, 9(8)：980．
[2] Issaq HJ, Veenstra TD, Conrads TP, et al．The SELDI-TOF MS approach to proteomics：Protein profiling and biomarker identification[J]. Bio-chem Biophy Res Communications, 2002, 292（3）：587-592．
[3] Issaq H,Conrads T, Prieto D, et al. SELDI-TOF MS for diagnostic proteomics[J].Anal Chem,2003,75(7):148A-155A.
[4] Kas K. On the technicalities of discovering and applying protein biomarkers for cancer prevention[J]. Eur J Cancer Prevention, 2004, 13(5):437-446.
[5] Merchant M, Weinberger S. Recent advancements in surface enhanced laser desorption/ ionization time of flight mass spectrometry[J]. Electrophoresis, 2000, 21（6）:1164-1177.
[6] El-Serag H, Mason A, Key C, et al. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United State[J]. Hepatology， 2001, 33:62-65.
[7] 吴孟超, 陈汉, 沈锋. 原发性肝癌的外科治疗——附5524例报告[J]. 中华外科杂志, 2001, 39(6):417-421.
[8] Poon TC, Chan AT, Zee B, et al. Application of classification tree and neural network algorithm to the identification of serological liver marker profiles in the diagnosis of hepatocellular carcinoma[J].Oncology,2001,61(4):275-283.
[9] Poon T, Yip T, Chan A, et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes[J]. Clin Chem, 2003, 49(5):752-760.
[10] Poon TC, Hui AY, Chan HL, et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: A pilot study[J]. Clin Chem, 2005, 52(2):328-335.
[11] Schwegler E, CazaresL, SteelL F, et al. SELDI-TOF-MS profiling of serum for detection of the progression of chronic hepatitis to hepatocellular carcinoma[J]. Hepatology, 2005, 41(3):634-642.
[12] Paradis V, Degos F, Dargere D, et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases[J]. Hepatology, 2005, 41(1):40-47.
[13] Ward DG, Cheng Y, N’Kontchou G, et al. Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis[J]. Br J Cancer, 2006, 94(2):287-292.
[14] Melle C, Kaufmann R, Hommann M, et al. Proteomic profiling in microdissected hepatocellular carcinoma tissue using protein chip technology[J]. Int J Oncol, 2004, 24(4):885-891.
[15] 车国卫, 周清华. 肺癌的筛查和早期诊断[J]. 中国肺癌杂志, 2003, 6(6):412-417.
[16] Wardwell N, Massion P. Novel strategies for the early detection and prevention of lung cancer[J]. Semin Oncol, 2005, 32(3):259-268.
[17] Zhukov T, Johanson R, Cantor A, et al. Discovery of distinct protein profiles specific for lung tumors and premalignant lung lesions by SELDI mass spectrometry[J]. Lung Cancer, 2003, 40(3):267-279.
[18] 杨拴盈, 肖雪媛, 张王刚, 等. 用蛋白质芯片技术筛选非小细胞肺癌患者血清中标志蛋白[J]. 中华结核和呼吸杂志, 2006, 29(1):31-34.
[19] Whitehouse C, Solomon E. Current status of t he molecular characterization of the ovarian cancer antigen CA125 and implications for it s use in clinical screening[J]. Gynecol Oncol, 2003, 88(1pt2):152-157.
[20] Petricion EF,Ardkani AM, Hitt BA, et al． Use of proteomic patterns in serum to identify ovarian cancer[J].Lancet, 2002, 359(9306)：572-577．
[21] Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakow KB, et al. Ovarian cancer marker of 11.7kDa detected by proteomics is a serum amyloidA1[J]. Proteomics, 2005, 24:56-62.
[22] 王琪, 李力, 黎丹戎, 等. 应用飞行时间质谱技术结合蛋白芯片筛选卵巢恶性肿瘤患者的血清标志物[J].中华妇产科杂志, 2006, 41(8):544-548.
[23] Li J, Zhang Z, Rosenzwwig J, et al． Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer[J].Clin Chem,2002,48(8):1296-1304．
[24] Fowler LJ, Lovell MO, Izbicka E. Fine-needle aspiration in PreservCyt: a novel and reproducible method for possible ancillary proteomic pattern expression of breast neoplasms by SELDI-TOF[J]. Mod Pathol, 2004, 17(8):1012-1020.
[25] Gretzer MB, Chan DW, Van Rootselaar CL, et al. Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF[J]. Prostate, 2004, 60(4):325-331.
[26] Albrethsen J, Bogebo R, Gammeltoft S, et al. Upregulated expression of human neutrophil peptides 1, 2 and 3(HNP 1-3) in colon cancer serum and tumours: a biomarker study[J]. BMC Cancer, 2005, 5:8.
[27] Wadsworth J, Kenneth D, Brendan C, et al. Identification of patients with head and neck cancer using serum protein profiles[J]. Arch Otolarygol Head Neck Surg, 2004, 130(1):98-104.
[28] Rosty C, Christa L, Kuzdzal S, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein Ⅰ as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology[J]. Cancer Res, 2002, 62(6):1868-1875.
[29] Ebert M, Meuer J, Wiemer JC, et al. Identification of gastric cancer patients by serum protein profiling[J]. Proteome Res, 2004, 3(6):1261-1266.
[30] Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems[J]. J Natl Cancer Inst, 2004, 96(5):353-356.
首页
